Hydrogenology
Hydrogenology editorial study record

Oral ‘hydrogen water’ induces neuroprotective ghrelin secretion in mice

Matsumoto A et al. · Sci Rep. 2013;3:3273.

PreclinicalOther formsPublished 2013
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Multiple controlled mouse ghrelin and MPTP-Parkinson-model experiments with pharmacologic blockade

Research topic

Parkinson’s disease

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adult mice in gastric-expression, plasma-ghrelin and MPTP neurotoxicity cohorts

Sample

Assay-specific groups ranged from n=2–10; for example n=4, n=5–10, n=4–5 and n=2–6 in principal figures

Duration

Four days for ghrelin experiments; seven days before MPTP and seven days of post-MPTP assessment

Intervention

Hydrogen water 0.8 mL/mouse once daily in ghrelin experiments and saturated H₂ water before MPTP in the Parkinson model

Hydrogen form

H₂ dissolved in oral water — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

Preparations ranged from about 0.04 mmol/L to saturated about 0.8 mmol/L H₂; magnesium-stick and open-air-electrolysis methods were used in different experiments.

H₂ flow

Not applicable — oral water, not gas inhalation; preparation flow was not reported.

O₂ delivered with H₂

No O₂ was co-delivered as part of the H₂ intervention.

Comparator

Control water with or without atenolol or a ghrelin-receptor antagonist and saline/MPTP controls

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Gastric ghrelin expression, plasma ghrelin and substantia-nigra dopaminergic-neuron measures

Reported result

The article reports increased ghrelin after four days and less MPTP-associated dopaminergic-neuron loss; atenolol or a ghrelin-receptor antagonist abolished the reported neuroprotection.

Results-extraction completeness

Preparation, concentrations, volume, schedules, assay-specific samples and antagonist results checked in the open-access full text.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Several small mechanistic mouse cohorts and three water-preparation methods; results do not establish benefit in people with Parkinson’s disease.

Applies directly to

Ghrelin signaling and MPTP neurotoxicity in mice.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 24253616 · DOI: 10.1038/srep03273

Publisher access

Open-access full text is available through PMC and Nature.

Extraction basis

Open-access PMC/Nature article and PubMed record; no retraction or expression of concern was shown in the checked records on 7 August 2026.

Record revision

2026-08-10